Trends in the administration of COVID-19 vaccines with other vaccines in the United States reported to V-safe during December 14, 2020—May 19, 2023

ABSTRACT

Introduction COVID-19 vaccines may be administered with other vaccines during the same healthcare visit. COVID-19 monovalent (Fall 2021) and bivalent (Fall 2022) vaccine recommendations coincided with annual seasonal influenza vaccination. Data describing the frequency of the co-administration of COVID-19 vaccines with other vaccines are limited. Methods We used V-safe, a voluntary smartphone-based U.S. safety surveillance system established by the CDC, to describe trends in the administration of COVID-19 vaccines with other vaccines reported to V-safe during December 14, 2020 – May 19, 2023. Results Of the 21 million COVID-19 vaccinations reported to V-safe, 2.2% (459,817) were administered with at least 1 other vaccine. Co-administration most frequently occurred during the first week of October 2023 (27,092; 44.1%). Most reports of co-administration included influenza vaccine (393,003; 85.5%). Co-administration was most frequently reported for registrants aged 6 months-6 years (4,872; 4.4%). Conclusion Reports of co-administration to V-safe peaked during October 2023, when influenza vaccination most often occurs, possibly reflecting increased opportunities for multiple vaccinations and greater acceptability of the co-administration of COVID-19 vaccine with other vaccines, especially influenza vaccine.

KEYWORDS:

• COVID-19 vaccine
• influenza vaccine
• co-administration
• V-safe

Acknowledgments

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC.

This project was supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the Centers for Disease Control and Prevention.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Author contributions statement

CP, AH, and DS contributed to the conception and design of the study. CP conducted data analyses and all authors were involved in the interpretation of the data. CP and AH contributed to the manuscript preparation. All authors critically revised the manuscript for intellectual content and approved the version to be published. All authors agree to be accountable for all aspects of the work.

Data availability statement

Data collected through V-safe from 12/13/2020 to 9/25/2022 is available from https://data.cdc.gov/Public-Health-Surveillance/v-safe-COVID-19/dqgu-gg5d/about_data.

Additional information

Funding

The author(s) reported that there is no funding associated with the work featured in this article.